Data from an early clinical trial of a small molecule drug intended to treat solid tumours by modulating an enzyme that plays a key role in the presentation of antigen to the human immune system were positive, according to the developer Grey Wolf Therapeutics Ltd. Data from the Phase 1/2 study were presented at the 2024 American Society of Clinical Oncology annual meeting on 3 June. The drug, GRWD5769 was well-tolerated after repeat dosing. It also showed an ability to modulate the immunopeptidome.
